Theratechnologies Inc.

Theratechnologies Inc.

June 23, 2015 10:03 ET

Theratechnologies Initiates Canadian Distribution of EGRIFTA™ (Tesamorelin for Injection)

Product Discovered and Developed in Canada

MONTREAL, QUEBEC--(Marketwired - June 23, 2015) - Theratechnologies Inc. (TSX:TH) is pleased to announce that EGRIFTA™ will be available to patients in Canada in the coming days as a first shipment of EGRIFTA™ was sent today to McKesson Canada`s specialty wholesale group, Theratechnologies' Canadian-based wholesaler, in order to fill its supply chain.

"We are especially proud to reach this new milestone. Discovering a new medical treatment and bringing it to market is something that very few Canadian biotech or pharma companies have been able to accomplish. Having our product available in our home country gives us a great sense of pride," said Mr. Luc Tanguay, President and Chief Executive Officer, Theratechnologies.

In addition, the availability of EGRIFTA™ in Canada will also enable AOP Orphan Pharmaceutical in Vienna, Austria, Theratechnologies' European partner, to initiate named-patients sales programs in Europe. Indeed, it will be the Canadian presentation of EGRIFTA™ that will be distributed through Theratechnologies' European partner.

"First quarter results for 2015 demonstrated the tangible and positive impact of regaining rights to EGRIFTA™ in the United States. The addition of new territories can only be beneficial to our overall objectives of becoming profitable and sustaining growth for the Company," added Mr. Tanguay.

The commercialization of EGRIFTA™ in Canada will be assumed by Theratechnologies through its own organization.

About Theratechnologies

Theratechnologies (TSX:TH) is a specialty pharmaceutical company addressing unmet medical needs in metabolic disorders to promote healthy aging and improved quality of life. Further information about Theratechnologies is available on the Company's website at and on SEDAR at

Forward-Looking Information

This press release contains forward-looking statements and forward-looking information, or, collectively, forward-looking statements, within the meaning of applicable securities laws, that are based on our management's belief and assumptions and on information currently available to our management. You can identify forward-looking statements by terms such as "may", "will", "should", "could", "would", "outlook", "believe", "plan", "envisage", "anticipate", "expect" and "estimate", or the negatives of these terms, or variations of them. The forward-looking statements contained in this press release include, but are not limited to, statements regarding the distribution of EGRIFTA™ by AOP Orphan Pharmaceutical in Europe through named patients sales programs and the growth and profitability of Theratechnologies through the addition of new territories.

Forward-looking statements are based upon a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Theratechnologies' control that could cause actual results to differ materially from those that are disclosed in or implied by such forward-looking information. These assumptions include, but are not limited to, the following: AOP will be successful in distributing EGRIFTA™ through named patients sales programs, EGRIFTA™ will be available in sufficient quantities to meet market demand in both Canada and in Europe, EGRIFTA™ will be accepted in Canada by healthcare professionals and patients and it will be on the list of reimbursed drugs in Canada and no unplanned material expenses will be incurred by Theratechnologies in the conduct of its activities.

These risks and uncertainties include, but are not limited to, the risk that regulatory changes prevent AOP from distributing EGRIFTA™ through named patient sales programs, market recall or market withdrawal of EGRIFTA™ occurs in the countries where EGRIFTA™ is commercialized, and the market penetration of EGRIFTA™ in Canada is very slow.

We refer potential investors to the "Risk Factors" section of our Annual Information Form dated February 25, 2015 available at for additional risks regarding Theratechnologies and its operations. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward-looking statements. Forward-looking statements reflect current expectations regarding future events and speak only as of the date of this press release and represent our expectations as of that date.

We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise, except as may be required by applicable law.

Contact Information

  • Luc Tanguay